Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway

ELUTIA INC.

2025-Q2 EPS reported -$1.89 vs consensus -$0.17 ▼ miss (-990.0%)

Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.
Total net sales flat at $6.3M; CanGaroo +19% to $2.6M, SimpliDerm +7% to $2.6M.
FDA clearance for EluPro received; manufacturing commenced; commercial team expanding.
Cash $18.2M at quarter end; $13.8M additional from post-quarter warrant exercises.
Adjusted EBITDA loss improved to $2.9M from $3.4M in prior-year quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.